BioSpace News Archive

ADMA Biologics, Inc. announced that it has received U.S. Food and Drug Administration approval for its eighth ADMA BioCenters plasma collection facility located in Hammond, Louisiana.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) today announced that it will host a Key Opinion Leader (KOL) Day focused on its lead immuno-oncology program BXCL701 for the investment community on Tuesday, February 21, 2023 from 1:00 to 3:00 p.m. ET.

EuMentis Therapeutics Inc., a privately-held biopharmaceutical company developing novel therapeutics for the treatment of neuropsychiatric diseases, today announced it has received an award from the United States Department of Defense (DoD) to develop a novel small molecule therapeutic targeting the extrasynaptic N-methyl-D-aspartate receptor (NMDAR) for the treatment of traumatic brain injury or “TBI.”

C4 Therapeutics, Inc. today announced that C4T management will participate in a fireside chat and a panel discussion at two upcoming virtual conferences in February.

Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference, being held virtually, on Wednesday, February 15, 2023 at 10:40 a.m. E.T.

Orchard Therapeutics today announced a series of presentations from across its neurometabolic portfolio will be featured at the 19th Annual WORLD Symposium taking place February 22-26, 2023, in Orlando, Florida.

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months and full year ended December 31, 2022.

SK bioscience announced that the company’s board of directors has officially decided to initiate the establishment of the ‘Songdo Global Research & Process Development Center.’

Generian Pharmaceuticals, Inc. announced that it has achieved the first research milestones for two programs in development under its collaboration agreement with Mitobridge, Inc.

Karyopharm Therapeutics Inc. today announced it will report fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023.